Product Overview
[Drug Name]
Generic Name: Irbesartan and Hydrochlorothiazide Tablets
Trade Name: YiLunPing Irbesartan and Hydrochlorothiazide Tablets (14 Tablets)
Pinyin Full Code: YiLunPing EBeiShaTanQingLvZuoZuoPian 14 Tablets
[Main Ingredients]
Each tablet contains 150mg of irbesartan and 12.5mg of hydrochlorothiazide.
[Indications/Main Functions]
YilunPing Irbesartan and Hydrochlorothiazide Tablets are used to treat essential hypertension. This fixed-dose combination is indicated for the treatment of patients whose blood pressure is inadequately controlled with irbesartan or hydrochlorothiazide alone.
[Specifications]
14 tablets (150mg:12.5mg) (YilunPing)
[Dosage and Administration]
Oral. YiLunPing Irbesartan and Hydrochlorothiazide Tablets: 2 tablets (irbesartan/hydrochlorothiazide: 150mg/12.5mg) once daily, taken on an empty stomach or with a meal. For patients whose blood pressure cannot be effectively controlled with irbesartan or hydrochlorothiazide alone. Adjustments to the dosage of either component (i.e., irbesartan or hydrochlorothiazide) are recommended. Once-daily doses exceeding 300 mg of irbesartan/25 mg of hydrochlorothiazide are not recommended. This product can be used in combination with other antihypertensive medications if necessary.
[Adverse Reactions]
Common adverse reactions of irbesartan include headache, dizziness, palpitations, and occasional cough. These are generally mild and transient, and most patients tolerate the medication well with continued use. Urticaria and angioedema are rare. Reported adverse reactions with an incidence greater than 1% include dyspepsia, heartburn, diarrhea, skeletal muscle pain, fatigue, and upper respiratory tract infection, but these reactions were not significantly different from the placebo group. Other adverse reactions reported with an incidence greater than 1% but lower than the placebo group include abdominal pain, anxiety, nervousness, chest pain, pharyngitis, nausea and vomiting, rash, and tachycardia. The incidence of hypotension and orthostatic hypotension is approximately 0.4%.
[Contraindications]
This product is contraindicated in patients with hypersensitivity.
[Drug Interactions]
Other Antihypertensive Medications: When this product is used in combination with other antihypertensive medications, its antihypertensive effect may be enhanced. Irbesartan and hydrochlorothiazide (at doses up to 300 mg/25 mg) can be safely used in combination with other antihypertensive medications and calcium channel blockers and receptor blockers. The use of irbesartan with or without thiazide diuretics may lead to volume depletion in patients who have previously received high-dose diuretics. This medication carries a risk of hypotension unless volume depletion is corrected.
[Precautions]
This product is contraindicated in patients with hypersensitivity to this product or its ingredients, or to other sulfonamides (hydrochlorothiazide is a sulfonamide). The following contraindications are associated with hydrochlorothiazide: 1. Severe renal impairment (creatinine clearance <30 m/min); 2. Refractory hypokalemia and hypercalcemia; 3. Severe hepatic impairment, biliary cirrhosis, and cholestasis.
[Pharmacology and Toxicology]
Hydrochlorothiazide in the irbesartan/hydrochlorothiazide combination formulation can activate the sympathetic nervous system and the renin-angiotensin system, counteracting its antihypertensive effects and lowering serum potassium levels. Irbesartan can counteract the compensatory mechanisms induced by diuretics, thereby enhancing the antihypertensive effect of diuretics. It also selectively blocks AT1 subtype receptors to exert its antihypertensive effect. Furthermore, irbesartan can attenuate the hydrochlorothiazide-induced increase in serum uric acid and decrease in serum potassium. Irbesartan/hydrochlorothiazide (r) effectively lowers blood pressure in patients with mild, moderate, or severe hypertension, comparable to ACE inhibitors, antagonists, and calcium channel blockers, used alone or in combination with hydrochlorothiazide. The increased efficacy of irbesartan and hydrochlorothiazide compared to monotherapy is crucial for achieving target blood pressures in treatment guidelines (JNC7 and WHO/ISH). Furthermore, the long-term tolerability of irbesartan/hydrochlorothiazide (r) and its simple, one-tablet daily dosing regimen may help patients adhere to treatment. Therefore, irbesartan and hydrochlorothiazide (r) are a reasonable choice for patients who must take combination medications to lower their blood pressure.
